Ulixertinib (BVD-523): A Comprehensive Monograph on a First-in-Class ERK1/2 Inhibitor

Executive Summary

Ulixertinib (also known as BVD-523) is an investigational, orally available, small molecule drug representing a first-in-class, highly selective, and potent inhibitor of the extracellular signal-regulated kinases 1 and 2 (ERK1/2). As a reversible, ATP-competitive inhibitor, Ulixertinib targets the terminal node of the mitogen-activated protein kinase (MAPK) signaling cascade, a pathway frequently hyperactivated in over a third of human cancers due to oncogenic mutations in genes such as BRAF and RAS. This mechanism provides a strong therapeutic rationale for its use in tumors driven by this pathway, and critically, offers a strategy to overcome acquired resistance to upstream MAPK inhibitors (e.g., BRAF and MEK inhibitors), which often involves the reactivation of ERK signaling.

Clinical development, led by BioMed Valley Discoveries, has established a recommended Phase II dose (RP2D) of 600 mg twice daily in adults, based on a foundational Phase I dose-escalation and expansion study (NCT01781429). This trial demonstrated preliminary but meaningful clinical activity, including durable partial responses in patients with advanced solid tumors harboring NRAS mutations, as well as both V600 and non-V600 BRAF mutations. Notably, responses were observed in patients who had previously progressed on BRAF and/or MEK inhibitor therapy, validating its core strategic application. However, the drug's efficacy is context-dependent, as a Phase II trial in metastatic uveal melanoma (NCT03417739), a disease driven by GNAQ/GNA11 mutations, failed to show objective responses.

The safety profile of Ulixertinib is considered acceptable but is characterized by significant on-target toxicities consistent with MAPK pathway inhibition in normal tissues. The most common treatment-related adverse events include dermatological toxicities (acneiform rash), gastrointestinal disturbances (diarrhea, nausea), and fatigue. These events are generally manageable but frequently necessitate dose reductions, highlighting a narrow therapeutic window that requires careful patient management.

Ulixertinib has received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA). An innovative Expanded Access Program (NCT04566393) is in place, providing compassionate use access while simultaneously generating valuable real-world evidence on novel combination therapies. The future of Ulixertinib likely resides in its use within combination regimens, targeting synergistic pathways or preventing resistance, a strategy supported by promising preclinical and early clinical data. Its development represents a significant advancement in targeting the MAPK pathway, offering a potential new therapeutic option for patients with difficult-to-treat, genetically defined cancers.

Chemical Profile and Pharmaceutical Properties

A precise understanding of a drug's chemical and physical properties is fundamental to its development, formulation, and clinical application. This section provides a definitive summary of Ulixertinib's nomenclature, identifiers, and key physicochemical characteristics.

Nomenclature and Identifiers

Ulixertinib is identified across scientific literature, clinical trial registries, and chemical databases by several names and codes. Its development history, from initial discovery to clinical advancement, has resulted in multiple synonyms being used interchangeably.

• Generic Name: The International Nonproprietary Name (INN) for the compound is Ulixertinib.[1]
• Code Names and Synonyms: The most common code name used in clinical development is BVD-523, reflecting its development by BioMed Valley Discoveries.[1] It is also known by its earlier code, VRT752271, from its discovery by Vertex Pharmaceuticals, and the descriptive name ERK inhibitor BVD-523.[4]
• IUPAC Name: The systematic chemical name is N--4-[5-chloro-2-(propan-2-ylamino)-4-pyridinyl]-1H-pyrrole-2-carboxamide.[1] Minor syntactic variations of this name appear in some databases but refer to the same chemical entity.[4]
• Key Database Identifiers: The compound is cataloged under specific identifiers in major international databases, which is crucial for accurate data retrieval and cross-referencing. The DrugBank accession number is DB13930.[8] The Chemical Abstracts Service (CAS) Registry Number for the free base form is 869886-67-9.[4] Related CAS numbers for its hydrochloride (HCl) salt (1956366-10-1) and HCl hydrate salt (1975172-95-2) have also been registered.[4] Other important identifiers are listed in Table 1.

The use of multiple synonyms (Ulixertinib, BVD-523, VRT752271) across different stages of development and in various publications necessitates a consolidated reference to prevent ambiguity. A comprehensive table of identifiers (Table 1) serves as a definitive key for researchers, facilitating accurate cross-database searches and ensuring precise identification of the compound in literature reviews and competitive intelligence analyses.

Physicochemical Characteristics

Ulixertinib is a synthetic organic small molecule belonging to the chemical classes of amines and pyridines.[1] Its physical properties influence its formulation as an oral therapeutic and its behavior in biological systems.

• Molecular Formula and Weight: The chemical formula for Ulixertinib is .[4] Its average molecular weight is consistently reported as 433.33 g/mol or 433.34 g/mol, with a monoisotopic mass of 432.1119814 Da.[4]
• Structural Information: The molecule's structure is defined by standard chemical notations:
• SMILES: CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl [8]
• InChIKey: KSERXGMCDHOLSS-LJQANCHMSA-N [4]
• Appearance and Purity: In its solid form, Ulixertinib is described as a white to off-white powder.[4] Commercial suppliers for research purposes have reported purities as high as 99.95%.[16]
• Solubility Profile: Ulixertinib exhibits poor aqueous solubility, a common characteristic of many small molecule kinase inhibitors that can pose formulation challenges. Its solubility is significantly higher in organic solvents.
• Water: Insoluble, with reported solubility of <1 mg/mL.[15]
• DMSO (Dimethyl sulfoxide): Highly soluble, with reported values of 70 mg/mL (161.54 mM) to 80 mg/mL (184.61 mM).[15]
• Ethanol: Soluble, with reported values of 12 mg/mL (27.69 mM) to 14 mg/mL (32.3 mM).[15]

This solubility profile necessitates formulation strategies, such as the use of co-solvents (e.g., PEG300, Tween-80) for preclinical in vivo studies, to achieve adequate bioavailability for oral administration.16

Table 1: Chemical and Pharmacological Identifiers for Ulixertinib
Identifier Type	Identifier
Generic Name (INN)	Ulixertinib
DrugBank ID	DB13930 8
CAS Number (Free Base)	869886-67-9 8
PubChem Compound ID (CID)	11719003 10
ChEMBL ID	CHEMBL3590106 8
NCI Thesaurus Code	C104744 8
KEGG ID	D11038 8
UNII	16ZDH50O1U 8
InChIKey	KSERXGMCDHOLSS-LJQANCHMSA-N 8

Pharmacology and Mechanism of Action

Ulixertinib's therapeutic potential is rooted in its precise molecular mechanism, targeting a critical control point in a signaling pathway fundamental to cancer cell growth and survival.

The MAPK/ERK Signaling Pathway in Oncology

The mitogen-activated protein kinase (MAPK) pathway, also known as the RAS-RAF-MEK-ERK cascade, is a central signaling network that transduces extracellular signals from growth factor receptors to the nucleus, regulating essential cellular processes such as proliferation, differentiation, survival, and apoptosis.[5] This pathway is organized as a tiered series of protein kinases, where RAS proteins activate RAF kinases, which in turn phosphorylate and activate MEK kinases (MEK1/2). MEK is the only known activator of the final kinases in the cascade, ERK1 and ERK2.[19]

In a substantial portion of human cancers—estimated to be over one-third—this pathway is constitutively activated due to mutations in its upstream components.[21] The most common of these are activating mutations in

RAS family genes (e.g., KRAS, NRAS) and BRAF. This aberrant, persistent signaling drives uncontrolled cell growth and is a hallmark of many aggressive malignancies, making the MAPK pathway a highly validated target for cancer therapy.[8]

Molecular Target and Binding Kinetics

Ulixertinib was specifically designed to inhibit the final, critical step of this oncogenic cascade.

• Primary Targets: The direct molecular targets of Ulixertinib are the serine/threonine kinases Extracellular signal-regulated kinase 1 (ERK1, encoded by the gene MAPK3) and Extracellular signal-regulated kinase 2 (ERK2, encoded by MAPK1).[2] As the terminal kinases in the cascade, ERK1/2 are responsible for phosphorylating over 160 substrates in both the cytoplasm and the nucleus, thereby executing the pathway's diverse biological functions.[11]
• Mechanism of Inhibition: Ulixertinib functions as a novel, reversible, ATP-competitive inhibitor.[1] This mechanism involves the drug molecule binding to the ATP-binding pocket of the ERK kinase domain. By directly competing with the cell's natural energy currency, adenosine triphosphate (ATP), Ulixertinib effectively blocks the kinase from transferring a phosphate group to its downstream substrates, thereby shutting down its catalytic activity.
• Potency and Selectivity: Ulixertinib is characterized by its high potency. Preclinical assays have demonstrated a half-maximal inhibitory concentration () of less than 0.3 nM against ERK2, indicating very strong binding and inhibition at sub-nanomolar concentrations.[4] Its developer, BioMed Valley Discoveries, has positioned the drug as a "highly selective" and "first-in-class" inhibitor. This selectivity is directed towards ERK1, ERK2, and the related kinase ERK8, with limited off-target inhibition of other kinases, a property that is hypothesized to contribute to its manageable safety profile compared to less selective inhibitors.[3]

Downstream Cellular Effects

By inhibiting ERK1/2, Ulixertinib prevents the activation of the entire downstream signaling program mediated by the MAPK pathway.[5] This blockade has profound consequences for cancer cells that are dependent on this pathway for their growth and survival. The primary antineoplastic effect is the inhibition of ERK-dependent tumor cell proliferation and the induction of apoptosis (programmed cell death).[4]

More detailed molecular studies, such as transcriptomic and proteomic analyses performed in neuroblastoma (NB) models, have provided a broader view of Ulixertinib's effects. These studies revealed that the drug not only inhibits the MAPK pathway but also downregulates other interconnected oncogenic and developmental pathways, including those driven by EGFR, VEGF, and WNT. Furthermore, proteomic analysis confirmed that Ulixertinib's effects converge on inhibiting the cell cycle and promoting apoptosis in cancer cells.[27]

Preclinical Evidence of Activity

The clinical development of Ulixertinib was built upon a strong foundation of preclinical data demonstrating its potential as an anti-cancer agent.

• Activity in MAPK-Mutant Models: In vitro and in vivo studies consistently showed that Ulixertinib has potent activity against cancer models with activating mutations in BRAF and RAS.[21] In xenograft models, where human tumors are grown in immunodeficient mice, Ulixertinib not only inhibited tumor growth but also induced tumor regression. This preclinical proof-of-concept directly informed the design of the pivotal Phase I clinical trial, which included specific expansion cohorts for patients with these mutations.
• Activity in Pediatric Cancers: Preclinical work in models of pediatric low-grade glioma (pLGG), a disease often driven by BRAF mutations or fusions, showed that Ulixertinib was active at clinically achievable nanomolar concentrations, with  values ranging from approximately 10 nM to 63 nM.[29]
• Reversal of Multidrug Resistance: An intriguing secondary activity was identified in preclinical studies investigating multidrug resistance (MDR). Ulixertinib, at concentrations that were not directly toxic to cells, was found to significantly reverse MDR mediated by the ATP-binding cassette (ABC) transporters ABCB1 (also known as P-glycoprotein) and ABCG2. It achieved this by directly inhibiting the efflux function of these pumps, which are notorious for expelling chemotherapy drugs from cancer cells.[4] This finding suggests a potential, though currently less explored, therapeutic application for Ulixertinib.

The preclinical data for Ulixertinib supports two distinct therapeutic rationales. The primary and most developed rationale is its function as a direct inhibitor of an oncogenic pathway, targeting the terminal ERK kinase in tumors that are "addicted" to MAPK signaling for their survival.[8] This is the foundation of its ongoing clinical program in oncology. A secondary, yet compelling, rationale emerges from its ability to reverse MDR.[4] This suggests a potential future role as a chemosensitizing agent, used in combination with conventional chemotherapies that are substrates for the ABCB1 or ABCG2 efflux pumps. This could be particularly relevant in treating chemo-refractory tumors, opening a separate avenue for future clinical investigation beyond its role as a targeted monotherapy.

Clinical Development and Efficacy Analysis

The translation of Ulixertinib from a promising preclinical compound to an investigational therapeutic has been guided by a strategic clinical development program designed to establish its safety, define its dose, and identify patient populations most likely to benefit.

Overview of the Clinical Program and Developers

Ulixertinib was originally discovered by Vertex Pharmaceuticals Incorporated.[9] Subsequently, the compound was licensed by BioMed Valley Discoveries (BVD), a clinical-stage biotechnology company and a subsidiary of the Stowers Institute for Medical Research.[1] BVD has since been responsible for advancing Ulixertinib through late-stage preclinical development and into a comprehensive program of clinical trials.[21] Across all investigated indications, the highest clinical trial phase that Ulixertinib has reached is Phase II.[2]

Foundational Phase I Study (NCT01781429)

The cornerstone of Ulixertinib's clinical evaluation is the first-in-human NCT01781429 trial, which provided the initial data on its safety, pharmacokinetics, and anti-tumor activity in humans.

• Design and Population: This was a multi-center study that enrolled 135 patients with advanced solid tumors. It employed an accelerated 3+3 dose-escalation design to determine the safe dose range, followed by six distinct dose-expansion cohorts to evaluate preliminary efficacy in specific, genetically defined patient populations.[22] The expansion cohorts were strategically designed based on preclinical data, focusing on patients with tumors harboring mutations in BRAF or NRAS (primarily melanoma) and other cancers with BRAF or MEK mutations.[22]
• Dosing and Key Outcome: The dose-escalation phase evaluated oral doses ranging from 10 mg to 900 mg twice daily (BID).[22] This phase successfully established the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) at 600 mg BID.[22] Pharmacodynamic analyses of patient blood samples confirmed that the 600 mg BID dose achieved near-complete inhibition of ERK kinase activity, demonstrating that a biologically effective concentration was reached and sustained.[22]
• Efficacy: The trial provided the first evidence of clinical activity. Across the dose-escalation and expansion cohorts, objective partial responses (PRs) were observed in 11% to 17% of evaluable patients.[22] These responses were concentrated in the targeted patient populations, including those with NRAS-mutant melanoma, BRAF V600-mutant solid tumors (such as lung cancer and glioblastoma), and, significantly, tumors with non-V600 BRAF mutations (e.g., G469A, L485W, D594G), for which there are few approved targeted therapies.[13] One of the most compelling findings was a durable response lasting over 24 months in a melanoma patient who was refractory to prior BRAF inhibitor therapy, providing strong clinical proof-of-concept for Ulixertinib's role in overcoming resistance.[28]

Studies in Hematological Malignancies (NCT02296242)

Beyond solid tumors, Ulixertinib was also evaluated in hematological cancers. A Phase 1/2 study (NCT02296242) was conducted in patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).[9] This trial has been completed, indicating that a full dataset on its safety and efficacy in this patient population has been collected, although specific outcomes were not detailed in the available documentation.

Evaluation in Uveal Melanoma (NCT03417739)

A dedicated trial was conducted to assess Ulixertinib in metastatic uveal melanoma, a rare and aggressive cancer with a distinct genetic profile.

• Rationale: Over 80% of uveal melanomas are driven by activating mutations in the genes GNAQ or GNA11. While these mutations are not in RAS or RAF, they lead to constitutive activation of the downstream MAPK pathway, providing a strong biological rationale for testing an ERK inhibitor.[37]
• Design and Outcome: The study (NCT03417739) was a Phase II trial using a Simon two-stage design, a common approach for single-arm studies to allow for early termination if a drug shows insufficient activity.[37] The trial was indeed terminated after the first stage due to a lack of efficacy. Among the 13 enrolled patients, no objective responses were observed. The best response was stable disease in four patients, and the median time to progression was a brief 2.0 months, indicating that ERK inhibition as a monotherapy is not an effective strategy in this disease.[37]

Pediatric Applications (NCI-COG Pediatric MATCH, APEC1621J)

Recognizing that many pediatric cancers are also driven by MAPK pathway alterations, Ulixertinib was evaluated in a pediatric population through the NCI-COG Pediatric MATCH trial.

• Design and Population: This "basket" trial (APEC1621J) enrolled patients aged 1 to 21 years with refractory malignancies that harbored specific genetic alterations known to activate the MAPK pathway.[38] As there were no prior pediatric data, the study included an initial dose-escalation phase.
• Key Outcome: The trial successfully established the pediatric RP2D at 260 mg/m²/dose PO BID. This dose is approximately 75% of the adult flat dose, adjusted for body surface area.[38]
• Efficacy: As a single agent in this heavily pre-treated and diverse pediatric population, Ulixertinib demonstrated limited activity. No objective responses were recorded. However, a signal of potential benefit was observed, as three patients with BRAF-altered low-grade central nervous system (CNS) tumors achieved prolonged stable disease lasting over six months.[38]

Combination Therapy Trials

A major focus of the ongoing development of Ulixertinib is its evaluation in combination with other anti-cancer agents. The rationale is to enhance efficacy, overcome both innate and acquired resistance, and target parallel survival pathways.[2]

• With Hydroxychloroquine (Autophagy Inhibitor): Based on preclinical findings that MAPK inhibition can induce a dependency on autophagy for tumor cell survival, Phase Ib/II trials (NCT04145297, NCT05221320) were initiated to evaluate Ulixertinib plus the autophagy inhibitor hydroxychloroquine in patients with advanced gastrointestinal malignancies.[2]
• With Palbociclib (CDK4/6 Inhibitor): A Phase 1b study combining Ulixertinib with the cell cycle inhibitor palbociclib in patients with advanced solid tumors (primarily pancreatic and colorectal cancer) was conducted. The study successfully established a MTD for the combination at Ulixertinib 450 mg BID plus palbociclib 125 mg daily on a standard schedule.[41]
• With KRASG12C Inhibitors: Strong preclinical data has shown that combining Ulixertinib with a KRASG12C inhibitor like adagrasib results in superior tumor growth inhibition compared to either drug alone. This suggests a promising strategy to deepen responses and circumvent the common resistance mechanisms to KRASG12C inhibitors, which often involve MAPK pathway reactivation.[39]
• With EGFR/BRAF Inhibitors: In colorectal cancer (CRC), where multiple pathways are often active, a Phase 1b study of Ulixertinib with cetuximab (an EGFR inhibitor) and encorafenib (a BRAF inhibitor) was initiated.[2] The potential of this approach was highlighted by a case report from the Expanded Access Program, where a patient with BRAF V600E-mutant CRC experienced a complete response to this triplet combination.[34]

The collective clinical data reveals that Ulixertinib's efficacy is highly dependent on the specific genetic context of the tumor. It demonstrates clear, albeit modest, activity in cancers driven by canonical RAS and RAF mutations, where the tumor is linearly "addicted" to ERK signaling for survival.[22] In stark contrast, its failure as a monotherapy in uveal melanoma suggests that while the MAPK pathway is activated in this disease, it may not be the sole critical driver of survival.[37] The upstream GNAQ/GNA11 mutations in uveal melanoma activate signaling through G-protein coupling, which may engage parallel survival pathways (such as the YAP/Hippo pathway) that are not fully dependent on ERK. This distinction underscores a crucial biological principle for patient selection: the identity of the upstream activating mutation is as important as the confirmation of downstream pathway activation. This finding refines the therapeutic hypothesis, indicating that Ulixertinib is most likely to be effective in tumors where ERK signaling is not just active, but is the dominant and indispensable driver of the malignant phenotype.

Table 2: Summary of Major Clinical Trials for Ulixertinib
NCT Identifier	Phase	Indication(s)	Status	Primary Purpose / Outcome
NCT01781429	Phase 1	Advanced Solid Tumors (with MAPK pathway mutations)	Active, not recruiting	Established adult RP2D of 600 mg BID; demonstrated preliminary efficacy in BRAF- and NRAS-mutant tumors.9
NCT02296242	Phase 1/2	Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)	Completed	To evaluate safety and efficacy in hematological malignancies.9
NCT03417739	Phase 2	Metastatic Uveal Melanoma	Recruiting	To evaluate efficacy; terminated early for lack of objective responses.9
APEC1621J (Pediatric MATCH)	Phase 2	Refractory Pediatric Malignancies (with MAPK alterations)	N/A	Established pediatric RP2D of 260 mg/m²/dose BID; showed limited single-agent activity.38
NCT02608229	Phase 1	Metastatic Pancreatic Cancer	Recruiting	To evaluate safety and efficacy of Ulixertinib in combination with nab-paclitaxel and gemcitabine.9
NCT04145297	Phase 1	Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas	Completed	To evaluate safety and efficacy of Ulixertinib in combination with hydroxychloroquine.40
NCT04566393	Expanded Access	Advanced MAPK Pathway-Altered Malignancies	Available	To provide compassionate use access and collect real-world data on monotherapy and combination therapies.42

Safety, Tolerability, and Risk Profile

A comprehensive evaluation of a drug's safety profile is paramount to understanding its clinical utility. The data from Ulixertinib's clinical trials provide a clear picture of its tolerability, characteristic adverse events, and the necessary considerations for patient management.

Overall Safety Assessment

At the adult RP2D of 600 mg BID, Ulixertinib is described as having an acceptable safety profile, with no drug-related deaths reported in the pivotal Phase I trial.[2] However, the on-target effects of inhibiting a fundamental signaling pathway lead to a notable incidence of adverse events. This is reflected in the high rate of dose reductions required to manage toxicities; in the Phase I expansion cohort, 32% of patients required at least one dose reduction, indicating that the therapeutic window between an effective dose and a poorly tolerated one can be narrow.[22]

Dose-Limiting Toxicities (DLTs)

Dose-limiting toxicities are severe adverse events that occur within the first cycle of treatment and are used to define the MTD. During the adult dose-escalation study, DLTs included dermatologic rash, diarrhea, elevated aspartate aminotransferase (AST), and elevated creatinine.[28] In the pediatric population, the spectrum of DLTs was broader, encompassing fatigue, anorexia, rash, various gastrointestinal toxicities (nausea, vomiting, diarrhea), dehydration, and electrolyte disturbances such as hypoalbuminemia and hypernatremia.[38]

Common Treatment-Related Adverse Events (TRAEs)

The toxicity profile of Ulixertinib is highly consistent with on-target inhibition of the MAPK pathway and shows significant overlap with the known side effects of MEK inhibitors.[45] These adverse events primarily affect tissues with high rates of cellular turnover, such as the skin and gastrointestinal tract.

• Gastrointestinal: GI-related toxicities are very common. Diarrhea was reported in 47-48% of patients, and nausea was reported in 37-41%, with vomiting also frequently observed.[22]
• Dermatological: Skin-related side effects are the most frequent class of TRAEs. Dermatitis acneiform (an acne-like rash) was reported in 29-49% of patients.[22] Other common skin issues include maculopapular rash (27%), pruritus (itching, ~25%), xerosis (dry skin, 11%), and photosensitivity (3%).[47]
• Constitutional: Systemic side effects are also prevalent, with fatigue being reported in 41-42% of patients.[22]
• Hematologic: When used as a monotherapy, hematologic toxicities are less prominent, but in combination regimens, particularly with cytotoxic chemotherapy like gemcitabine and nab-paclitaxel, high rates of anemia, thrombocytopenia (low platelets), and neutropenia (low white blood cells) were observed.[48]
• Ophthalmologic: Ocular side effects have been noted, including blurred vision and visual floaters.[46] Due to the known risk of ocular toxicity with MAPK pathway inhibitors, patients with a history or current risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) have been consistently excluded from clinical trials.[42]

The pattern of adverse events associated with Ulixertinib is not random but rather represents an "on-target" toxicity fingerprint, stemming directly from the inhibition of a fundamental signaling pathway that is also active in normal tissues. The high incidence of dermatological and gastrointestinal events are classic class effects shared with MEK inhibitors, confirming the drug's mechanism of action.[45] A subtle but important distinction is the absence of reported cases of paronychia (inflammation of the nail folds), a toxicity commonly seen with EGFR inhibitors, which suggests a more selective kinase inhibition profile that may spare certain downstream effects associated with EGFR signaling.[47] The necessity for dose reductions in nearly a third of patients underscores that managing these on-target toxicities is a critical component of treatment.[22] Proactive supportive care, including dermatologic consultations for rash and early intervention for diarrhea, is essential to maintain dose intensity, which is often correlated with therapeutic efficacy.

Severe (Grade ≥3) Adverse Events

While most adverse events are Grade 1 or 2, more severe events can occur. In the Expanded Access Program, Grade 3 or 4 serious adverse events (SAEs) were reported in 31% of patients.[34] Specific Grade ≥3 events reported across various trials include elevations in liver function tests (AST/ALT), hyponatremia (low sodium), severe pruritus, elevated amylase, anemia, and severe rash or diarrhea.[37] In a trial combining Ulixertinib with gemcitabine and nab-paclitaxel, one fatal (Grade 5) case of pneumonitis (lung inflammation) was reported, highlighting the increased risk profile when combining with cytotoxic agents known to have pulmonary toxicity.[48]

Table 3: Consolidated Profile of Common Treatment-Related Adverse Events (All Grades)
Adverse Event	Reported Incidence Range (%)
Dermatitis Acneiform / Rash	29 - 49 22
Diarrhea	19 - 48 22
Fatigue	25 - 42 22
Nausea	37 - 54 22
Pruritus	~25 47
Anorexia (Decreased Appetite)	15 34
Vomiting	Not specified, but common 46
Dry Skin (Xerosis)	11 47
Alopecia (Hair Changes)	~10 47
Photosensitivity	3 47

Regulatory Status and Patient Access

The regulatory pathway for an investigational drug provides insight into its perceived clinical potential and the strategy for its development. Ulixertinib has benefited from several U.S. FDA programs designed to accelerate the availability of promising new therapies.

United States FDA Designations

The U.S. Food and Drug Administration (FDA) has granted Ulixertinib two important designations that have facilitated its development.

• Orphan Drug Designation: On June 24, 2013, Ulixertinib received Orphan Drug Designation for the "Treatment of Stage IIb through Stage IV BRAF mutant melanoma".[2] This status is granted to drugs intended to treat rare diseases or conditions (affecting fewer than 200,000 people in the U.S.) and provides incentives such as tax credits for clinical trials and potential market exclusivity upon approval.
• Fast Track Designation: In September 2015, the FDA granted Ulixertinib Fast Track Designation.[21] This program is designed to facilitate development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.[51] The designation was specifically noted for patients with solid tumors harboring certain non-V600 BRAF mutations (G469A, L485W, or L597Q), for which there are no approved targeted therapies.[53] Benefits of this designation include more frequent meetings with the FDA and the potential for a "rolling review" of the New Drug Application (NDA).

Expanded Access Program (EAP) (NCT04566393)

To provide access to the drug for patients outside of formal clinical trials, a robust Expanded Access Program (EAP), also known as "compassionate use," has been established.

• Purpose and Sponsorship: The program (NCT04566393), sponsored by the clinical study platform provider xCures in collaboration with BVD, was launched in September 2020. Its objective is to provide Ulixertinib for compassionate use to patients with advanced MAPK pathway-altered solid tumors who have exhausted all available standard therapies and are not eligible to enroll in other Ulixertinib clinical trials.[32]
• Eligibility: The program is open to adolescent (aged ≥ 12 years) and adult patients in the U.S. with solid tumors that have a documented activating mutation in the MAPK pathway, including in genes such as KRAS, NRAS, HRAS, BRAF, MEK, or ERK.[42]
• Unique Program Feature: A key feature of this EAP is its flexibility. It permits treatment with Ulixertinib either as a monotherapy or as part of a combination regimen, with the choice of the companion agent(s) left to the discretion of the treating physician.[34] This design transforms the program from a simple access vehicle into a powerful platform for generating prospective real-world evidence (RWE). Clinical data on safety and outcomes are systematically collected in a regulatory-compliant database, providing valuable information on the drug's performance in a broader, more heterogeneous patient population and on novel combination strategies that can inform future formal trials.[34]

The regulatory and access strategy for Ulixertinib reflects a modern approach to drug development. The early acquisition of Orphan and Fast Track designations was a conventional and effective tactic to de-risk and accelerate the development process.[21] The subsequent establishment of a highly flexible EAP, managed by a specialized platform company, represents a more novel and agile strategy.[32] This program serves a dual purpose: it provides critical access for patients with no other options, while simultaneously functioning as a hypothesis-generating engine. By allowing physicians to test rational combinations in real-world settings, the EAP can identify promising new therapeutic strategies—such as the complete response observed in a CRC patient treated with a triplet combination—that can then be validated in more structured Phase II or III trials.[34] This approach marks a shift from rigid, traditional clinical trial paradigms to a more dynamic, data-driven model that can accelerate learning and optimize development pathways.

International Regulatory Landscape

As of the latest available information, Ulixertinib's regulatory filings have been concentrated in the United States.

• European Medicines Agency (EMA): A review of available resources indicates no specific designation, marketing authorization application, or approval for Ulixertinib within the European Union.[56]
• Therapeutic Goods Administration (TGA), Australia: Similarly, there is no evidence of an application for or approval of Ulixertinib in Australia.[1]

Strategic Analysis and Future Outlook

Ulixertinib's position as a late-stage clinical candidate requires a strategic analysis of its competitive landscape, its core therapeutic value proposition, and the key questions that will shape its future development and potential clinical role.

Comparative Positioning: Ulixertinib vs. Other ERK Inhibitors

While several ERK inhibitors are currently in various stages of clinical development (e.g., ONC201, LY3214996) [61], BioMed Valley Discoveries has positioned Ulixertinib as both "first-in-class" and "best-in-class".[2] The "first-in-class" claim is based on its status as one of the most clinically advanced novel ERK1/2 inhibitors. The "best-in-class" argument is predicated on its differentiated molecular profile. This profile is defined by its high selectivity for the intended targets (ERK1, ERK2, and ERK8) with limited off-target kinase inhibition. This high degree of selectivity is hypothesized to be the reason for its relatively favorable and manageable tolerability profile, distinguishing it from other investigational ERK inhibitors that have reportedly faced more significant challenges with dosing and off-target toxicities.[3]

The Core Strategy: Overcoming Resistance to Upstream MAPK Inhibition

The primary strategic value of an ERK inhibitor lies in its unique position within the MAPK signaling cascade. As the final kinase in the pathway, ERK represents a critical convergence point for all upstream signals, whether they originate from mutated RAS, RAF, or other activating events.[3] The most common mechanism of acquired resistance to upstream inhibitors, such as BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi), is the reactivation of the pathway at or downstream of the inhibited kinase, ultimately restoring ERK signaling.[19] Therefore, inhibiting ERK directly provides a logical and powerful strategy to overcome this resistance.

The pivotal Phase I trial for Ulixertinib provided the first clinical proof-of-concept for this strategy. The observation of durable responses in melanoma patients who had already progressed on prior BRAFi and/or MEKi therapy was a landmark finding.[23] This result validates the core therapeutic hypothesis and establishes the most critical and commercially viable path forward for Ulixertinib: as a treatment for patients whose tumors remain dependent on the MAPK pathway after failing initial lines of targeted therapy.

Future Research Directions and Unanswered Questions

Despite its promise, several key questions remain that will guide the future development of Ulixertinib.

• Optimal Combination Strategies: The long-term success of Ulixertinib will almost certainly be in combination regimens. The central challenge is identifying the most synergistic and tolerable partners. Strong preclinical data support combinations with KRASG12C inhibitors to prevent resistance.[39] Early clinical data has shown promise and established safe dosing for combinations with CDK4/6 inhibitors (palbociclib) and multi-agent regimens in CRC (cetuximab/encorafenib).[34] Future trials will need to systematically evaluate these and other rational combinations, such as with PI3K/AKT/mTOR pathway inhibitors, to address parallel survival pathways.
• Biomarker Development: The current patient selection biomarker is the presence of any activating MAPK pathway mutation. However, the failure of Ulixertinib in GNAQ/GNA11-mutant uveal melanoma demonstrates that this is insufficient. Future research must focus on identifying more refined biomarkers that can predict not just pathway activation, but true pathway "addiction," to distinguish responders from non-responders.
• Sequencing and Timing: The optimal placement of an ERK inhibitor in the cancer treatment algorithm is unknown. Should Ulixertinib be reserved for salvage therapy after BRAFi/MEKi failure, as currently demonstrated? Or could it be more effective if used upfront in combination with a BRAFi or MEKi to prevent or delay the emergence of resistance from the outset? Answering this question will require large, randomized clinical trials.
• Expansion to New Indications: Preclinical data suggests potential activity in other MAPK-driven cancers like neuroblastoma and pediatric low-grade glioma.[27] While single-agent activity was limited in the pediatric MATCH trial, the signal of prolonged stable disease in low-grade gliomas warrants further investigation, likely in combination with other agents.[38]

While targeting the terminal kinase in the MAPK pathway is a potent strategy for overcoming upstream resistance, it also presents a fundamental challenge. The MAPK pathway is not exclusive to cancer cells; it is essential for the normal function of many healthy tissues. Unlike inhibiting a mutated oncogene that is largely tumor-specific (e.g., BRAF V600E), global inhibition of wild-type ERK1/2 in all tissues inevitably leads to significant on-target toxicities, as evidenced by the prominent dermatological and gastrointestinal side effects. This creates a narrow therapeutic index, where the dose required for robust anti-tumor efficacy is close to the dose that causes intolerable side effects for the patient, a fact reflected in the 32% dose reduction rate observed in the Phase I trial.[22] Consequently, the ultimate clinical success of Ulixertinib and the entire class of ERK inhibitors will depend on skillfully navigating this challenge. The path forward will likely involve the development of intermittent dosing schedules, the identification of synergistic combinations that allow for lower, better-tolerated doses of Ulixertinib, or the discovery of specific patient populations whose tumors are so exquisitely dependent on ERK signaling that they respond to doses that remain manageable for the patient as a whole.

Works cited

1. ulixertinib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 30, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9210
2. Ulixertinib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 30, 2025, https://synapse.patsnap.com/drug/70f8e919dea34350b1bdd29d4cd55016
3. Ulixertinib | Biomed Valley Discoveries, accessed September 30, 2025, https://biomed-valley.com/ulixertinib/
4. Ulixertinib free base | VRT752271 | BVD-523 | CAS#869886-67-9 - MedKoo Biosciences, accessed September 30, 2025, https://www.medkoo.com/products/4485
5. Definition of ulixertinib - NCI Drug Dictionary, accessed September 30, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ulixertinib
6. ulixertinib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 30, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=9210
7. ulixertinib - My Cancer Genome, accessed September 30, 2025, https://www.mycancergenome.org/content/drugs/ulixertinib/
8. Ulixertinib | C21H22Cl2N4O2 | CID 11719003 - PubChem, accessed September 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ulixertinib
9. CAS 869886-67-9 Ulixertinib - BOC Sciences, accessed September 30, 2025, https://www.bocsci.com/product/ulixertinib-cas-869886-67-9-460061.html
10. pubchem.ncbi.nlm.nih.gov, accessed September 30, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/Ulixertinib#:~:text=VRT752271%20HCl-,(S)%2D4%2D(5%2Dchloro%2D2%2D(isopropylamino,%2Dpyrrole%2D2%2Dcarboxamide.](https://www.google.com/url?q=https://pubchem.ncbi.nlm.nih.gov/compound/Ulixertinib%23:~:text%3DVRT752271%2520HCl-,(S)%252D4%252D(5%252Dchloro%252D2%252D(isopropylamino,%252Dpyrrole%252D2%252Dcarboxamide.&sa=D&source=editors&ust=1759223732075301&usg=AOvVaw0QuthCUSP1Q1k-ncl0TvYQ)
11. Ulixertinib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 30, 2025, https://go.drugbank.com/drugs/DB13930
12. Ulixertinib | CAS 869886-67-9 | SCBT - Santa Cruz Biotechnology, accessed September 30, 2025, https://www.scbt.com/p/ulixertinib-869886-67-9
13. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/29247021/
14. Compound: ULIXERTINIB (CHEMBL3590106) - ChEMBL - EMBL-EBI, accessed September 30, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3590106
15. Ulixertinib (BVD-523, VRT752271) | ERK1/ERK2 inhibitor | Buy from Supplier AdooQ®, accessed September 30, 2025, https://www.adooq.com/vrt752271.html
16. Ulixertinib | ERK - TargetMol, accessed September 30, 2025, https://www.targetmol.com/compound/ulixertinib
17. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health | Oncotarget, accessed September 30, 2025, https://www.oncotarget.com/article/240/text/
18. A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer - PMC, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6827047/
19. Dual-mechanism ERK1/2 inhibitors exploit a distinct binding mode to block phosphorylation and nuclear accumulation of - Astex Pharmaceuticals, accessed September 30, 2025, https://astx.com/wp-content/uploads/2019/12/Dual-mechanism-ERK1-2-inhibitors-exploit-a-distinct-binding-mode-to-block-phosphorylation-and-nuclear-accumulation-of-ERK1-2-resulting-in-enhanced-potency.pdf
20. A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer, accessed September 30, 2025, https://www.researchgate.net/publication/336760389_A_Comprehensive_Review_on_MAPK_A_Promising_Therapeutic_Target_in_Cancer
21. First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models | Biomed Valley Discoveries, accessed September 30, 2025, https://biomed-valley.com/news_releases/first-in-class-erk-inhibitor-ulixertinib-bvd-523-shows-promise-in-preclinical-cancer-models/
22. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study | Cancer Discovery - AACR Journals, accessed September 30, 2025, https://aacrjournals.org/cancerdiscovery/article/8/2/184/6164/First-in-Class-ERK1-2-Inhibitor-Ulixertinib-BVD
23. First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. - ASCO Publications, accessed September 30, 2025, https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.2508
24. Selleck Chemical LLC Ulixertinib (BVD-523) 5mg 869886-67-9 VRT752271, Quantity, accessed September 30, 2025, https://www.fishersci.com/shop/products/ulixertinib-5mg-1/501366392
25. Ulixertinib (hydrochloride) (BVD-523, VRT-752271, CAS Number: 1956366-10-1), accessed September 30, 2025, https://www.caymanchem.com/product/18298/ulixertinib-(hydrochloride)
26. pubchem.ncbi.nlm.nih.gov, accessed September 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ulixertinib#:~:text=Upon%20oral%20administration%2C%20ulixertinib%20inhibits,tumor%20cell%20proliferation%20and%20survival.
27. ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo - PMC, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9688897/
28. First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. - ASCO, accessed September 30, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT192360
29. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10013652/
30. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/35882450/
31. Ulixertinib by BioMed Valley Discoveries for Hematological Tumor: Likelihood of Approval, accessed September 30, 2025, https://www.pharmaceutical-technology.com/data-insights/ulixertinib-biomed-valley-discoveries-hematological-tumor-likelihood-of-approval/
32. xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523), accessed September 30, 2025, https://www.biospace.com/xcures-announces-the-launch-of-a-compassionate-use-program-for-ulixertinib-bvd-523
33. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study - AACR Journals, accessed September 30, 2025, https://aacrjournals.org/cancerdiscovery/article-pdf/8/2/184/1809449/184.pdf
34. Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523). - ASCO Publications, accessed September 30, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e15101
35. ERK Inhibition: A New Front in the War against MAPK Pathway ..., accessed September 30, 2025, https://aacrjournals.org/cancerdiscovery/article/8/2/140/6299/ERK-Inhibition-A-New-Front-in-the-War-against-MAPK
36. ANLL Completed Phase 1 / 2 Trials for Ulixertinib (DB13930) | DrugBank Online, accessed September 30, 2025, https://go.drugbank.com/indications/DBCOND0042650/clinical_trials/DB13930?phase=1%2C2&status=completed
37. A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma | Cancer Research Communications - AACR Journals, accessed September 30, 2025, https://aacrjournals.org/cancerrescommun/article/4/5/1321/745436/A-Phase-II-Study-of-ERK-Inhibition-by-Ulixertinib
38. Phase II Study of Ulixertinib in Children and Young Adults with ..., accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11639582/
39. Abstract 2692: The combination of ulixertinib (ERK1/2 Inhibitor) and KRAS G12C inhibition demonstrates significant efficacy in preclinical models - AACR Journals, accessed September 30, 2025, https://aacrjournals.org/cancerres/article/83/7_Supplement/2692/719465/Abstract-2692-The-combination-of-ulixertinib-ERK1
40. Ulixertinib Completed Phase 1 Trials for Gastrointestinal Neoplasms Treatment - DrugBank, accessed September 30, 2025, https://go.drugbank.com/drugs/DB13930/clinical_trials?conditions=DBCOND0028304&phase=1&purpose=treatment&status=completed
41. A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors. - ASCO, accessed September 30, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT331965
42. Study Details | NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies | ClinicalTrials.gov, accessed September 30, 2025, https://www.clinicaltrials.gov/study/NCT04566393
43. Study Details | NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies | ClinicalTrials.gov, accessed September 30, 2025, https://clinicaltrials.gov/study/NCT04566393
44. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study | Cancer Discovery, accessed September 30, 2025, https://aacrjournals.org/cancerdiscovery/article-abstract/8/2/184/6164
45. Promising Activity Seen from ERK1/2 Inhibitor in MAPK/ERK Mutations and BRAF/MEK Resistance | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways, accessed September 30, 2025, https://www.targetedonc.com/view/promising-activity-seen-from-erk12-inhibitor-in-mapkerk-mutations-and-brafmek-resistance
46. phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ) - Cholangiocarcinoma Foundation, accessed September 30, 2025, http://www.cholangiocarcinoma.org/phase-2-basket-trial-of-ulixertinib-bvd-523-in-combination-with-hydroxychloroquine-in-patients-with-advanced-gastrointestinal-malignancies-harboring-mapk-pathway-mutations-bvd-523-hcq/
47. Characterization and Management of ERK Inhibitor Associated Dermatologic Adverse Events: Analysis from a Nonrandomized Trial of Ulixertinib for Advanced Cancers - PMC, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9282166/
48. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma | The Oncologist | Oxford Academic, accessed September 30, 2025, https://academic.oup.com/oncolo/article/28/2/e115/6847157
49. Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma - PMC - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9245552/
50. Search Orphan Drug Designations and Approvals - FDA, accessed September 30, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=398213
51. Fast Track | FDA, accessed September 30, 2025, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
52. Fast Track Designation Request Performance - FDA, accessed September 30, 2025, https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/fast-track-designation-request-performance
53. A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC). | Journal of Clinical Oncology - ASCO Publications, accessed September 30, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS3172
54. FDA Grants Expanded Access Program to Ulixertinib for MAPK Pathway Aberrant Cancer, accessed September 30, 2025, https://www.cancernetwork.com/view/fda-grants-expanded-access-program-to-ulixertinib-for-mapk-pathway-aberrant-cancer
55. NCT04566393 : Clinical Trial Detail - Cancer Knowledgebase (CKB), accessed September 30, 2025, https://ckb-core.genomenon.com/clinicalTrial/show?nctId=NCT04566393
56. Ulixertinib - BioMed Valley Discoveries - AdisInsight - Springer, accessed September 30, 2025, https://adisinsight.springer.com/drugs/800037542
57. Lazcluze | European Medicines Agency (EMA), accessed September 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/lazcluze
58. National registers of authorised medicines | European Medicines Agency (EMA), accessed September 30, 2025, https://www.ema.europa.eu/en/medicines/national-registers-authorised-medicines
59. Provisional application receives approval through the first international collaborative review initiative between TGA, FDA and HC, accessed September 30, 2025, https://www.tga.gov.au/news/media-releases/provisional-application-receives-approval-through-first-international-collaborative-review-initiative-between-tga-fda-and-hc
60. Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy, accessed September 30, 2025, https://telixpharma.com/news-views/australian-tga-approves-additional-indication-for-telixs-illuccix-to-include-patient-selection-for-psma-targeted-therapy/
61. Targeting RAS–RAF–MEK–ERK signaling pathway in human ..., accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10066287/